TM-38837
(Redirected from TM38837)
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing it from being verifiable and neutral. (April 2011) |
.svg) | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H20Cl2F3N7O |
| Molar mass | 586.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.[1] The company has announced phase I clinical trials.
TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference [2] but is now known from a more recent reference.[3]
See also
[edit]References
[edit]- ↑ "7TM Pharma". Archived from the original on July 7, 2011. Retrieved January 18, 2011.
- ↑ Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, et al. (September 2010). "Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist". ChemMedChem. 5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID 20652930. S2CID 34244587.
- ↑ Cooper ME, Nørregaard PK, Andersson G, Linget JM, Högberg T, Little PB, Receveur JM, Elling CE (December 2025). "Efficacy of the Hepatotropic Peripheral CB1R Inverse Agonist TM38837 in Rat Models of Obesity and Metabolic Syndrome". J. Mol. Clin. Med. 8 (1) 36687. doi:10.31083/jmcm36687.
External links
[edit] | This cannabinoid related article is a stub. You can help Wikipedia by adding missing information. |